Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Head Neck ; 38(8): 1234-41, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27028310

RESUMO

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and minorities have the worst survival. However, the molecular mechanisms underlying survival disparities have not been elucidated. METHODS: In a retrospective study, we assessed association between HNSCC early death (<2 years) and 208 somatic mutations of 10 cancer-related genes in 214 patients: 98 non-Hispanic whites (46%), 72 Hispanic whites (34%), and 44 African Americans (20%). RESULTS: Hispanic whites and African Americans had significantly higher mutation rates for EGFR, HRAS, KRAS, and TP53. HNSCC early death was significantly associated with 3+ mutations (odds ratio [OR] = 2.78, 95% confidence interval [CI] = 1.16, 6.69), NOTCH1 mutations in non-Hispanic whites (OR = 5.51; 95% CI = 1.22-24.83) and TP53 mutations in Hispanic whites (OR = 3.84; 95% CI = 1.08-13.68) in multivariable analysis adjusted for age, sex, tumor site, and tumor stage. CONCLUSION: We have provided the proof-of-principal data to link racial/ethnic-specific somatic mutations and HNSCC prognosis and pave the way for precision medicine to overcome HNSCC survival disparities. © 2016 Wiley Periodicals, Inc. Head Neck 38:1234-1241, 2016.


Assuntos
Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/mortalidade , Etnicidade/genética , Neoplasias de Cabeça e Pescoço/genética , Neoplasias de Cabeça e Pescoço/mortalidade , Grupos Raciais/genética , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/terapia , Estudos de Coortes , Bases de Dados Factuais , Intervalo Livre de Doença , Etnicidade/estatística & dados numéricos , Feminino , Genes erbB-1/genética , Neoplasias de Cabeça e Pescoço/patologia , Neoplasias de Cabeça e Pescoço/terapia , Disparidades nos Níveis de Saúde , Humanos , Incidência , Estimativa de Kaplan-Meier , Modelos Logísticos , Masculino , Análise Multivariada , Mutação , Proteínas Proto-Oncogênicas p21(ras)/genética , Grupos Raciais/etnologia , Receptor Notch1/genética , Estudos Retrospectivos , Medição de Risco , Carcinoma de Células Escamosas de Cabeça e Pescoço , Análise de Sobrevida , Proteína Supressora de Tumor p53/genética , Estados Unidos
2.
Biopreserv Biobank ; 13(4): 280-6, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26280502

RESUMO

Within the past three decades, the significance of banking human cancer tissue for the advancement of cancer research has grown exponentially. The purpose of this article is to detail our experience in collecting brain tumor specimens in collaboration with the University of Miami/Sylvester Tissue Bank Core Facility (UM-TBCF), to ensure the availability of high-quality samples of central nervous system tumor tissue for research. Successful tissue collection begins with obtaining informed consent from patients following institutional IRB and federal HIPAA guidelines, and it needs a well-trained professional staff and continued maintenance of high ethical standards and record keeping. Since starting in 2011, we have successfully banked 225 brain tumor specimens for research. Thus far, the most common tumor histology identified among those specimens has been glioblastoma (22.1%), followed by meningioma (18.1%). The majority of patients were White, non-Hispanics accounting for 45.1% of the patient population; Hispanic/Latinos accounted for 23%, and Black/African Americans accounted for 14%, which represent the particular population of the State of Florida according to the 2010 census data. The most common tumors found in each subgroup were as follows: Black/African American, glioblastoma and meningioma; Hispanic, metastasis and glioblastoma; White, glioblastoma and meningioma. The UM-TBCF is a valuable repository, offering high-quality tumor samples from a unique patient population.


Assuntos
Neoplasias Encefálicas/patologia , Manejo de Espécimes/métodos , Bancos de Tecidos , Adulto , Negro ou Afro-Americano , Encéfalo/patologia , Neoplasias Encefálicas/etnologia , Coleta de Dados , Feminino , Florida , Glioblastoma/patologia , Hispânico ou Latino , Humanos , Imuno-Histoquímica , Masculino , Meningioma/patologia , Pessoa de Meia-Idade , Universidades , População Branca
3.
Ear Nose Throat J ; 92(6): E59, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23780608

RESUMO

We report what is to the best of our knowledge the first case of malignant transformation of a giant cell tumor of the larynx. The patient, a 34-year-old man, presented to our tertiary care university teaching hospital where he underwent hemilaryngopharyngectomy with radial forearm free flap reconstruction and 11 of 15 cycles of chemotherapy. He remained disease-free at approximately 6 years and 4 months of follow-up. The patient is decannulated and continues to have a good voice with excellent quality of life to this day. We discuss the patient's clinical course and subsequent treatment within the context of a review of the current literature regarding this disease entity. Our experience demonstrates that giant cell tumor of the larynx may present as a malignant neoplasm without adversely affecting the patient's prognosis when treated aggressively with surgical resection and adjunct chemotherapy.


Assuntos
Transformação Celular Neoplásica , Tumor de Células Gigantes do Osso/patologia , Neoplasias Laríngeas/patologia , Adulto , Tumor de Células Gigantes do Osso/etiologia , Tumor de Células Gigantes do Osso/cirurgia , Humanos , Neoplasias Laríngeas/etiologia , Neoplasias Laríngeas/cirurgia , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA